Literature DB >> 8783496

Alterations in T cells of cancer-bearers: whence specificity?

D L Levey1, P K Srivastava.   

Abstract

T cells of tumor-bearing mice and cancer patients have been reported to have altered signal-transduction machinery. These alterations have been implicated in immunological suppression. Here, Daniel Levey and Pramod Srivastava critically examine the evidence for these alterations in the context of the tumor specificity of immunological unresponsiveness in tumor-bearing hosts.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8783496     DOI： 10.1016/0167-5699(96)10013-X

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  10 in total

1.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 2.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors:  Dominic Smethurst
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

Review 4.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

5.  A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods.

Authors:  A M Deakin; K Singh; J S Crowe; J H Ellis; A Dalgleish; R J Leicester; C J Finlayson; W F Miles; P F Life
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.

Authors:  Vino T Cheriyan; Cessal Thomas; Prabha Balaram
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

Review 7.  Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

Authors:  K Hellstrand; M Brune; C Dahlgren; M Hansson; S Hermodsson; P Lindnér; U H Mellqvist; P Naredi
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

8.  Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine.

Authors:  M Eric Kohler; William H D Hallett; Qing-Rong Chen; Javed Khan; Bryon D Johnson; Rimas J Orentas
Journal:  Cell Immunol       Date:  2010-07-17       Impact factor: 4.868

9.  Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes.

Authors:  T D de Gruijl; H J Bontkes; F Peccatori; M P Gallee; T J Helmerhorst; R H Verheijen; J Aarbiou; W M Mulder; J M Walboomers; C J Meijer; N van de Vange; R J Scheper
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

10.  Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.

Authors:  Ezogelin Oflazoglu; Mark Elliott; Hiroshi Takita; Soldano Ferrone; Robert A Henderson; Elizabeth A Repasky
Journal:  J Transl Med       Date:  2007-06-25       Impact factor: 5.531
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.